Tag: 爱上海HA

Parking space row leaves Guyanese man dead in NYC

No Comments

first_imgA Guyanese man died on Sunday morning after he was struck down by an irate driver, who drove his car into a crowd after slashing two other men during a row over parking space on Liberty Avenue near 127th Street in Richmond Hill, Queens, New York. Dead is 22-year-old Richardo Chatergoon of Far Rockaway, Queens. The suspect, Adrian Harry, 22, was on Monday charged with murder, assault, and reckless endangerment.Reports are that at 04:00h, Harry scraped a parked BMW while trying to parallel park his white Hyundai Sonata. This resulted in a heated argument among the suspect and two men, during which he whipped out a knife and slashed the victims.After committing the act, he allegedly drove his car into a half-dozen good Samaritans who had intervened. Chatergoon was one of those six people.The others hospitalised include a 29-year-old man with a head injury, a 27-year-old with a hurt leg, a 29-year-old man with a broken pelvis and a 20-year-old woman who suffered a broken leg.After fleeing the scene, the suspect was arrested. According to the New York Post, Harry was held at the 106th Precinct station house in Ozone Park until his court appearance on Monday.Chatergoon migrated to the United States about 18 months ago, to live with his family.last_img read more

NeuroTrauma Sciences and Henry Ford join hands to advance exosome technology

No Comments

first_imgJul 16 2018NeuroTrauma Sciences, LLC (NTS), a biopharmaceutical company, and Henry Ford Health System, a non-profit organization, today announce that a newly-formed subsidiary of NTS has entered into multi-year Sponsored Research and License Agreements. The new company is named NeurExo Sciences, LLC (NXS) and its goal is to advance Henry Ford’s pioneering technology involving exosomes as extracellular vesicles enriched with microRNA for the purpose of treating stroke, traumatic brain injury (TBI) including concussion, and neuropathies.Under the Agreements, NXS will license methods and intellectual property (IP) from Henry Ford and fund exosome research projects headed by principal investigator Michael Chopp, Ph.D., Vice Chairman, Department of Neurology, Scientific Director, Neurosciences Institute, at Henry Ford Hospital. NXS will gain worldwide commercial rights to product candidates resulting from the IP and sponsored research coming out of the lab.Related StoriesNew therapy shows promise in preventing brain damage after traumatic brain injurySlug serves as ‘command central’ for determining breast stem cell healthRepurposing a heart drug could increase survival rate of children with ependymomaDr. Chopp and his research team have generated proof-of-principle data in a number of small and large animal models showing how exosomes can amplify the body’s own neurological repair mechanisms and potentially improve long-term neurological outcomes following brain injury, such as stroke or TBI, and neurodegenerative diseases (link to Dr. Chopp’s research here).”Our studies in multiple pre-clinical models indicate that exosomes have the potential to provide significant therapeutic benefits to enhance the recovery from stroke or traumatic brain injury, and potentially with a better safety profile and greater efficacy than their parent or progenitor cells,” said Dr. Chopp. “Success of this novel approach may lead to a shift in the treatment paradigm for TBI, stroke and neurological disease.””We are delighted to collaborate with Dr. Chopp and his research team to advance the next generation of cell-based therapies,” said Carl Long, NeuroTrauma Sciences and NeurExo Sciences Co-founder and Chief Executive Officer. “We believe that exosome technology has the potential to serve as a transformational platform for multiple neurological conditions – including stroke, concussion and other traumatic brain injuries – and NeuroTrauma Sciences is excited to be a part of it.””Henry Ford researchers are pioneers in the exosome field and the NeuroTrauma Sciences team recognized the tremendous potential of our technology and world leading scientists,” said Mark Coticchia, Vice President & Chief Innovation Officer of Henry Ford Health System. “We appreciate their support in pursing the development of this cutting-edge technology with these Agreements, and their commitment to investing in the broader Detroit scientific community with the formation of this new company.” Source:https://www.henryford.com/last_img read more